New Hope for Cystic Fibrosis Patients with Rare Mutations as Gene Therapy Advances

Emily Kramer-Golinkoff, 40, lives with advanced cystic fibrosis (CF), a life-threatening genetic disorder affecting approximately 40,000 people in the United States. Unlike most CF patients who benefit from existing treatments, Emily’s condition stems from a rare genetic mutation that renders current therapies ineffective. Her daily struggle to breathe and perform basic activities highlights a critical gap in genetic medicine: many patients with uncommon mutations remain underserved.

The Challenge of Rare Mutations in Genetic Diseases

Cystic fibrosis is caused by defects in the CFTR protein, which leads to thick, sticky mucus buildup in the lungs and other organs. While recent “CFTR modulator” therapies have transformed the lives of patients with the most common mutations-improving lung function and quality of life-these drugs do not help those like Emily, whose mutations are rare or poorly understood.

Dr. Kiran Musunuru, a gene editing expert at the University of Pennsylvania, explains the dilemma as “mutational discrimination,” where pharmaceutical companies prioritize treatments for the largest patient populations to justify market investments. This leaves patients with rare mutations with limited options and diminished hope.

Breaking Barriers Through Mutation-Agnostic Gene Therapies

In response, researchers and advocacy groups are pushing for “mutation-agnostic” gene therapies that could potentially treat all CF patients regardless of their specific genetic mutation. These therapies aim to deliver a correct version of the CF gene into patients’ cells, enabling the production of normal CFTR protein and bypassing the need to target individual mutations.

Emily’s nonprofit organization, Emily’s Entourage, has been instrumental in funding early-stage gene therapy research. Spirovant Sciences, supported by this foundation, launched a clinical trial in November at Columbia University to test a gene therapy designed for any CF mutation. This 53-week trial will evaluate the treatment’s safety and longevity in the lungs.

Hope Amidst Ongoing Challenges

Emily’s condition has worsened over time, with only 30% lung capacity, kidney issues, and diabetes requiring insulin. Despite these challenges, she remains hopeful: “Just having these therapies in trials brings a tremendous amount of hope.” Her story underscores the urgent need for inclusive genetic treatments that do not leave minority mutation groups behind.

The broader issue extends beyond cystic fibrosis. Many genetic disorders show similar disparities, where patients with rare mutations or those from underrepresented populations face limited treatment options due to a lack of genetic testing and research diversity. Efforts to expand genetic screening and develop universal therapies are crucial steps toward equitable healthcare.

Looking Forward

The promise of mutation-agnostic gene therapies offers a beacon of hope for patients like Emily and thousands of others worldwide. While these treatments may still be years away from widespread availability, ongoing clinical trials and advocacy efforts are paving the way for a future where no patient is left behind due to the rarity of their genetic mutation.

Disclaimer

This article is based on information available as of April 27, 2025, including a report by The Associated Press. Gene therapy is an emerging field, and while clinical trials show promise, these treatments are still experimental and not yet widely accessible. Patients should consult healthcare professionals for personalized medical advice. The content is for informational purposes only and does not constitute medical advice or endorsement of any specific therapy or company.